Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules

Tadanori Yamada, Joohee Jung, Masaharu Seno, Akihiko Kondo, Masakazu Ueda, Katsuyuki Tanizawa, Shun'ichi Kuroda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.

Original languageEnglish
Pages (from-to)702-705
Number of pages4
JournalCold Spring Harbor Protocols
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

Viral Envelope Proteins
Electroporation
Viruses
Cell Culture Techniques
Cell culture
Liver
Hepatitis B Vaccines
Proteins
Peptide Receptors
Heterografts
Small Interfering RNA
Plasmids
Yeasts
Yeast
Ligands
Antibodies
Genes
Cells
Tissue
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules. / Yamada, Tadanori; Jung, Joohee; Seno, Masaharu; Kondo, Akihiko; Ueda, Masakazu; Tanizawa, Katsuyuki; Kuroda, Shun'ichi.

In: Cold Spring Harbor Protocols, Vol. 7, No. 6, 06.2012, p. 702-705.

Research output: Contribution to journalArticle

Yamada, Tadanori ; Jung, Joohee ; Seno, Masaharu ; Kondo, Akihiko ; Ueda, Masakazu ; Tanizawa, Katsuyuki ; Kuroda, Shun'ichi. / Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules. In: Cold Spring Harbor Protocols. 2012 ; Vol. 7, No. 6. pp. 702-705.
@article{202b6ac470f0462eb6f66d11d4416eee,
title = "Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules",
abstract = "Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.",
author = "Tadanori Yamada and Joohee Jung and Masaharu Seno and Akihiko Kondo and Masakazu Ueda and Katsuyuki Tanizawa and Shun'ichi Kuroda",
year = "2012",
month = "6",
doi = "10.1101/pdb.prot069534",
language = "English",
volume = "7",
pages = "702--705",
journal = "Cold Spring Harbor Protocols",
issn = "1559-6095",
publisher = "Cold Spring Harbor Laboratory Press",
number = "6",

}

TY - JOUR

T1 - Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules

AU - Yamada, Tadanori

AU - Jung, Joohee

AU - Seno, Masaharu

AU - Kondo, Akihiko

AU - Ueda, Masakazu

AU - Tanizawa, Katsuyuki

AU - Kuroda, Shun'ichi

PY - 2012/6

Y1 - 2012/6

N2 - Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.

AB - Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84862151886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862151886&partnerID=8YFLogxK

U2 - 10.1101/pdb.prot069534

DO - 10.1101/pdb.prot069534

M3 - Article

VL - 7

SP - 702

EP - 705

JO - Cold Spring Harbor Protocols

JF - Cold Spring Harbor Protocols

SN - 1559-6095

IS - 6

ER -